Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
Date:9/22/2008

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population.

CASODEX is currently approved in the US at a dose of 50 mg daily tablet for use in combination with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of advanced prostate cancer (metastatic Stage D2).

AstraZeneca has a well-established prostate cancer portfolio including hormonal treatments CASODEX, launched in 1995, and ZOLADEX(R) (goserelin acetate implant), launched in 1989. Three Phase III clinical research trials (ENTHUSE program) are currently underway to evaluate the safety and effectiveness of an investigational compound, ZD4054, in non-metastatic and metastatic hormone-resistant prostate cancer.

About Prostate Cancer

Over 186,000 men will be diagnosed with prostate cancer in the U.S. in 2008, making it the most frequently diagnosed cancer in men.(1) After lung cancer, prostate cancer is the second leading cause of cancer death in men, with an estimated 28,660 deaths in 2008.(2) One in six men will develop prostate cancer in his lifetime.

About CASODEX(R) (bicalutamide) Tablets

CASODEX at a dose of 50 mg daily is a prescription medication approved for use in combination with an injection of a luteinizing hormone-releasing hormone analog (LHRH-A) for treatment of advanced prostate cancer (metastatic Stage D2).

CASODEX at a dose of 150 mg daily is not approved for use alone or with other treatments. See full Prescribing Information under the section on "CLINICAL PHARMACOLOGY-Clinical Studies-Safet
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
2. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
3. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
4. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
5. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
6. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
10. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
11. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Feb. 10, 2011 ,We are in a State of ... message that concerned Florida residents are desperate for people to hear. ... day due to prescription drug abuse and statistics show it is ... (FAADA) is calling for an immediate Congressional hearing to help put ...
... Feb. 10, 2011 For the biopharmaceutical industry, ... - and difficulty - of interacting with patients ... have created both opportunities and challenges for approaching ... To help marketing teams in the ...
Cached Medicine Technology:Parents, Physicians Unite and Declare: State of Emergency 2Parents, Physicians Unite and Declare: State of Emergency 3Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... carcinoma but relatively few patients are cured. Combined neoadjuvant ... survival but there is concern about treatment morbidity and ... research team from China used a prospective study, based ... postoperative CRT to surgery alone in patients with resectable ...
... idiopathic skeletal hyperostosis (DISH) is a common but ... people. All papers related to DISH demonstrate a ... advancing age. Various local structural lesions such as ... cervical osteophytes may lead to mechanical esophageal dysphagia. ...
... beyond the liver, researchers say , FRIDAY, April 9 ... virus are at much higher risk of developing kidney ... than 67,000 patients enrolled in the Henry Ford Health ... with hepatitis C developed kidney cancer. That,s double the ...
... , FRIDAY, April 9 (HealthDay News) -- Nearly half ... school-aged children are due to overuse -- and many ... the message from the just-launched Stop Sports Injuries campaign, ... and elite athletes, including professional golf legend Jack Nicklaus; ...
... ... New York Clinical Information Exchange, based in Buffalo, NY, has selected the Anakam to ... ... 9, 2010 -- Anakam announced today that HEALTHeLINK the Western New York Clinical Information ...
... Singapore ... procedures. With success rates topping 90 percent across a range of complex surgeries, the country ... ... National Eye Centre (SNEC) is the first and only specialist eye centre outside of ...
Cached Medicine News:Health News:Perioperative chemoradiotherapy in esophageal squamous cell carcinoma 2Health News:More Kids Falling Prey to Sports Overuse Injuries 2Health News:More Kids Falling Prey to Sports Overuse Injuries 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 2Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 4Health News:Singapore Performs Cutting-edge Eye Surgeries 2Health News:Singapore Performs Cutting-edge Eye Surgeries 3Health News:Singapore Performs Cutting-edge Eye Surgeries 4Health News:Singapore Performs Cutting-edge Eye Surgeries 5
Female High Waist Briefs...
Provides upper and lower arm and flank support. Extends to the wrist and over the full upper back. Has a thin strap above the breast and a 3 waistband for a secure, comfortable fit. Made of soft span...
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Breast Augmentation Wrap...
Medicine Products: